drugset / Trial / NCT00026260

SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT00026260

Treatment

Summary

RATIONALE: Biological therapy with drugs such as SU5416 may stop the growth of cervical cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have persistent or recurrent cervical cancer.

Timeline

Start
Primary completion
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Subject semaxanib Small molecule Intravenous

Indications